Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 1 November 1974:
Vol. 186. no. 4162, pp. 454 - 456
DOI: 10.1126/science.186.4162.454
Prev | Table of Contents | Next

Articles

Evidence for in vivo Reaction of Antibody and Complement to Surface Antigens of Human Cancer Cells

Kenji Irie 1, Reiko F. Irie 1, and Donald L. Morton 1

1 Division of Oncology, Department of Surgery, Center for Health Sciences, Los Angeles, California 90024, and Surgical Service, Veterans Administration Hospital, Sepulveda, California 91343

The immune adherence test was used to determine whether antibody and complement in cancer patients are fixed in vivo to tumor cells. Human erythrocytes adhered in vitro to the surface of human cancer cells obtained from autopsy and biopsy. Adherence was enhanced by further addition of the C2 and C3 components of complement, and was diminished by preliminary treatment with antibody to C3 (that is, to beta1C-globulin). The results suggest that tumor associated membrane antigens form complexes in vivo with antibodies and complement.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
A. D. Kennedy, M. D. Solga, T. A. Schuman, A. W. Chi, M. A. Lindorfer, W. M. Sutherland, P. L. Foley, and R. P. Taylor (2003)
Blood 101, 1071-1079
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)